TOP OF THE NEWS
Myriad Genetics may spin off pharma biz
FDA clears AlloMap test
BUSINESS NEWS
Nanogen to merge with Elitech Group
Meridian Bioscience inks Canadian distribution deal
Pathwork Diagnostics raises $20 million
Pall Corp. acquires GeneSystems
INSIDE DIAGNOSTICS INDUSTRY
Interview with Nanogen’s David Ludvigson
SCIENCE/TECHNOLOGY
New gene variant linked to prostate cancer risk
Protein variant predicts chemotherapy response
REGULATORY NEWS
Physicians frustrated by CMS’s quality reporting initiative feedback
FINANCIAL NEWS
IVD stocks down 6%
G-2 INSIDER
Biomarker for soft tissue sarcoma

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

October 2008 - Table of Contents

DTTR October 2008 (full PDF issue)

Myriad Genetics May Spin Off Pharma Business

FDA Clears Third IVDMIA: XDx’s AlloMap

Nanogen to Merge With French Diagnostics Company

Meridian Bioscience Inks Canadian Distribution Deal

Inside the Diagnostics Industry: Nanogen’s David Ludvigson on Mergers, Markets, and Microarrays

New Gene Variant Linked to Prostate Cancer Risk

Protein Variant Predicts Chemotherapy Response

Pathwork Diagnostics Raises $20 Million

Pall Corporation Acquires GeneSystems

Physicians Frustrated by CMS’s Quality Reporting Initiative Feedback

IVD Stocks Down 6%; OraSure, Luminex Only Gainers

Biomarker for Soft Tissue Sarcoma